www.veronapharma.com
Open in
urlscan Pro
76.76.21.61
Public Scan
Submitted URL: http://www.veronapharma.com/
Effective URL: https://www.veronapharma.com/
Submission: On October 12 via api from US — Scanned from DE
Effective URL: https://www.veronapharma.com/
Submission: On October 12 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
VisionStrategyCompany LeadershipCorporate Governance About Ensifentrine Patients Stock InformationNews & SEC FilingsEvents & PresentationsFinancial ResultsAnalyst CoverageShareholder Information Investors Media Careers Contact BREATH OF INNOVATION® VERONA PHARMA IS DEVELOPING LIFE ENHANCING TREATMENTS FOR RESPIRATORY DISEASES. VERONA PHARMA ANNOUNCES ENSIFENTRINE MEETS PRIMARY ENDPOINT IN PHASE 3 ENHANCE-2 TRIAL FOR COPD Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. Find out more WE’RE A CLINICAL‑STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING INNOVATIVE PRESCRIPTION MEDICINES. We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker. THE UNMET NEED →COPD CYSTIC FIBROSIS ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS A PROGRESSIVE RESPIRATORY DISEASE WITHOUT A CURE. The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Pulmonary Disease. Find out more LATEST NEWS View all news August 29 2022 VERONA PHARMA TO PRESENT AT H.C. WAINWRIGHT 24TH ANNUAL GLOBAL INVESTMENT CONFERENCE Regulatory August 24 2022 VERONA PHARMA STRENGTHENS COMMERCIALIZATION LEADERSHIP TEAM Regulatory August 19 2022 NUANCE PHARMA RECEIVES CLEARANCE TO BEGIN PIVOTAL CLINICAL TRIALS WITH ENSIFENTRINE FOR COPD IN CHINA Regulatory Latest Film ENSIFENTRINE IS A PHASE 3, FIRST-IN-CLASS CANDIDATE FOR THE MAINTENANCE TREATMENT OF COPD VERONA PHARMA About Us Ensifentrine Patients Media Contact INVESTOR INFORMATION Stock Information News & SEC Filings Events & Presentations Financial Results Shareholder Information Analyst Coverage © Verona Pharma plc 2022. All rights reserved Email Alerts | Website Terms & Conditions | Legal Information THIS SITE USES COOKIES We use anonymous analytical cookies. Third-parties with tools on this site also use cookies. You can find out more here I understand